Physician profile
Edwin Carmouche
NPI 1649468083
$13,812.83
in general payments reported to CMS, 2019-2025
26 companies · $2,203 in 2025
The $2,203 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,932 · 2020: $1,233 · 2021: $1,956 · 2022: $1,906 · 2023: $2,137 · 2024: $2,447 · 2025: $2,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,752 · Education: $34.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,751.73 |
| Education | $34.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,681.96 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $3,200.84 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,695.46 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Insmed, INC. | $933.59 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $643.09 | 2021-2025 | Tyvaso |
| Genzyme Corporation | $400.03 | 2024-2025 | |
| Grifols USA, LLC | $358.87 | 2019-2023 | Prolastin-C Liquid |
| Amgen INC. | $327.54 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $262.54 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $181.81 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $165.37 | 2019-2024 | Yupelri |
| Pulmonx Corporation | $156.47 | 2019-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Genentech USA, INC. | $131.74 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $130.59 | 2019-2021 | |
| Inspire Medical Systems, INC. | $111.25 | 2023-2024 | Inspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $90.13 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $88.36 | 2022-2025 | Glassia |
| Electromed, INC. | $76.31 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $55.43 | 2019-2020 | |
| Philips North America LLC | $33.22 | 2020-2023 | |
| Paratek Pharmaceuticals, INC. | $26.73 | 2023-2024 | Nuzyra |
| Viatris Specialty LLC | $14.50 | 2025 | Yupelri |
| Circassia INC. | $13.59 | 2020 | |
| Merck Sharp & Dohme LLC | $13.12 | 2021 | |
| Shire North American Group INC | $11.64 | 2019 | |
| Inogen, INC. | $8.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Carmouche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.